¹⁸F-FDG PET/CT参数在淋巴瘤患者预后评估中的研究进展

关键词

淋巴瘤 / PET/CT / 疗效评估

[1] 中国临床肿瘤学会. 淋巴瘤18F-FDG应用指南 2021[M]. 北京:人民卫生出版社,2021:13-37 .
[2] 汤泊,周东亚,刘敏,等. 治疗前¹⁸F-FDG PET/CT显像代谢参数对老年经典型霍奇金淋巴瘤的预后价值[J]. 中华核医学与分子影像杂志,2022,42(4):6.
[3] Eisazadeh R, Mirshahvalad SA.¹⁸F-FDG PET/CT prognostic role in predicting response to salvage therapy in relapsed/refractory Hodgkin's lymphoma[J]. Clinical Imaging, 2022, 92: 25-31.
[4] 乔文礼,牛家华,金文雅,等. 自体干细胞移植前或后¹⁸F-FDG PET/CT显像及相关因素对经典霍奇金淋巴瘤预后的预后价值[J]. 中华核医学与分子影像杂志,2020,40(3):147-152.
[5] Mettler J, Müller H, Voltin CA, et al.Metabolic tumor volume for response prediction in advanced-stage Hodgkin lymphoma[J]. Journal of Nuclear Medicine, 2019, 60(2): 207-211.
[6] Aldin A, Umlauff L, Estcourt LJ, et al. Interim PET‐results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta‐analysis of prognostic factor studies[J]. Cochrane Database of Systematic Reviews, 2020,1(1): CD012643.
[7] Pavlovsky A, Fernandez I, Kurgansky N, et al.PET‐adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial[J]. British Journal of Haematology, 2019, 185(5): 865-873.
[8] Bakst RL, Campbell BA, Pinnix CC.PET guided therapy for early stage Hodgkin lymphoma: are we positive about a negative interim scan?[J]. International Journal of Radiation Oncology Biology Physics, 2020, 107(1): 12-17.
[9] Rekowski J, Hüttmann A, Schmitz C.Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ΔSUVmax Method[J]. J Nucl Med,2021,62(1): 37-42.
[10] Casasnovas RO, Bouabdallah R, Brice P, et al.PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study[J]. The Lancet Oncology, 2019, 20(2): 202-215.
[11] 万欢,刘鹏,梁颖,等. ¹⁸F-氟代脱氧葡萄糖正电子发射计算机断层扫描在治疗后霍奇金淋巴瘤预后预测中的作用[J]. 中华肿瘤杂志,2021,43(12):1275-1281.
[12] Cottereau AS, Meignan M, Nioche C, et al.Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT(dagger)[J]. Ann Oncol, 2021, 32(3): 404-411.
[13] Ceriani L, Gritti G, Cascione L, et al.SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model[J]. Blood Adv, 2020, 4(6): 1082-1092.
[14] 李佳苗,曹小梅,李冬菊,等. ¹⁸F-FDG PET/CT扩散参数联合肿瘤代谢体积评估弥漫大B细胞淋巴瘤患者预后[J]. 中国医学影像技术,2023,39(9):1359-1363.
[15] Rekowski J, Hüttmann A, Schmitz C, et al.Interim PET evaluation in diffuse large B-cell lymphoma using published recommendations: comparison of the Deauville 5-point scale and the ΔSUVmax method[J]. Journal of Nuclear Medicine, 2021, 62(1): 37-42.
[16] 郑立春,张欢,顾程,等. ¹⁸F-FDG PET/CT Deauville评分及ΔSUVmax评估弥漫性大B细胞淋巴瘤化疗中期预后的价值[J]. 实用临床医药杂志,2023,27(4):85-90.
[17] 贺慧慧,吴小红,杜晓庆,等. ¹⁸F-FDG PET/CT Deauville评分和IHP标准在弥漫性大B细胞淋巴瘤疗效评估中的应用[J]. 中华核医学与分子影像杂志,2019,39(5):266-271.
[18] 吴冯春,张召奇,赵新明,等. 化疗结束时 ¹⁸F-FDG PET/CT Lugano淋巴瘤疗效评估标准与弥漫性大B细胞淋巴瘤预后的关系[J]. 中华核医学与分子影像杂志,2022,42(4):209-215.
[19] 蒋冲,来瑞鹤,滕月,等. 基线¹⁸F-FDG PET/CT代谢参数及相关临床因素在非特指性外周T细胞淋巴瘤中的预后评估价值[J]. 中华核医学与分子影像杂志,2022,42(6):347-351.
[20] Zhang Y, Wang G, Zhao X, et al.The Role of Pre-Treatment and Mid-Treatment ¹⁸F-FDG PET/CT Imaging in Evaluating Prognosis of Peripheral T-Cell Lymphoma-Not Otherwise Specified (PTCL-NOS)[J]. BMC Medical Imaging, 2021, 21(1): 145-145.
[21] Gong H, Li T, Li J, et al.Prognostic value of baseline total metabolic tumour volume of ¹⁸F-FDG PET/CT imaging in patients with angioimmunoblastic T-cell lymphoma[J]. EJNMMI Research,2021,11(1):64.
[22] Gong H Tang B, Li T, et al. The added prognostic values of baseline PET dissemination parameter in patients with angioimmunoblastic T-cell lymphoma[J]. EJHaem, 2022, 4(1):67-77.
[23] Hu L, Luo N, Li L, et al.A preliminary investigation of the relationship between ¹⁸F-FDG PET/CT metabolic parameters and prognosis in angioimmunoblastic T-cell lymphoma[J]. Frontiers in Oncology,2023, 13:1171048.
[24] 彭攀,吴宁,陶秀丽,等. ¹⁸F-脱氧葡萄糖正电子发射计算机断层扫描对结外NK/T细胞淋巴瘤的疗前评估价值[J]. 中华肿瘤杂志,2022,44(4):370-376.
[25] 张亚飞,王珍,林丽莉,等. 治疗前¹⁸F-FDG PET/CT SUVmax 对Ⅰ~ Ⅱ期鼻型 NK/T细胞淋巴瘤的预后判断价值[J]. 中华核医学与分子影像杂志,2018,38(9):602-604.
[26] Wang H, Shen G, Jiang C, et al.Prognostic value of baseline, interim and end-of-treatment ¹⁸F-FDG PET/CT parameters in extranodal natural killer/T-cell lymphoma: A meta-analysis[J]. PLoS One, 2018, 13(3): e0194435.
[27] Guo R, Xu P, Xu H, et al.The predictive value of pre-treatment ¹⁸F-FDG PET/CT on treatment outcome in early-stage extranodal natural killer/T-cell lymphoma[J]. Leukemia Lymphoma, 2020, 61(11): 2659-2664.
[28] Mathew B, Vijayasekharan K, Shah S, et al.Prognostic Value of ¹⁸F-FDG PET/CT-Metabolic Parameters at Baseline and Interim Assessment in Pediatric Anaplastic Large Cell Lymphoma[J]. Clinical Nuclear Medicine, 2020, 45(3):182-186.
[29] Moon SH, Lee AY, Kim WS.Value of interim FDG PET/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma[J]. Leukemia Lymphoma, 2017, 58(6):1341-1348.
[30] Xu P, Guo R, You J.Dynamic evaluation of the prognostic value of ¹⁸F-FDG PET/CT in extranodal NK/T-cell lymphoma, nasal type[J]. Annals of Hematology, 2021, 100(4): 1039-1047.
[31] Chen X, Zhao S, Wang H.Assessment of the prognostic value of interim fluorodeoxyglucose positron emission tomography/computed tomography in nasal-type extranodal natural killer/T-cell lymphoma[J]. Quant Imaging Med Surg,2021,11(4): 1220-1233.
[32] Jiang C, Liu J, Li L.Predictive approaches for post-therapy PET/CT in patients with extranodal natural killer/T-cell lymphoma: a retrospective study[J]. Nuclear Medicine Communications, 2017, 38(11):937-947.
[33] Li H, Wang M, Zhang Y,et al.Prediction of prognosis and pathologic grade in follicular lymphoma using ¹⁸F-FDG PET/CT[J]. Front Oncol,2022,12: 943151.
[34] Yang Q, Luo Y, Zhang Y,et al.Baseline ¹⁸F-FDG PET/CT may predict the outcome of newly diagnosed follicular lymphoma in patients managed with initial "watch-and-wait" approach[J]. European Radiology,2022,32(8):5568-5576.
[35] Boo SH, O JH, Kwon SJ. Predictive Value of Interim and End-of-Therapy ¹⁸F-FDG PET/CT in Patients with Follicular Lymphoma[J]. Nucl Med Mol Imaging,2019,53(4): 263-269.
[36] Zhou Y, Zhao Z, Li J.Prognostic values of baseline, interim and end-of therapy ¹⁸F-FDG PET/CT in patients with follicular lymphoma[J]. Cancer Manag Res,2019,11: 6871-6885.